EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AKT Phosphorylation of FOXK2 at Ser398 Impacts Breast Cancer Cell Growth and Viability

L T Carneiro iD, J M R C Nunes iD, G De Gregoriis iD, B S Mendonça iD, W M Araújo iD, R C Maia iD, E W F Lam iD, R S Carvalho iD, M A Carvalho iD, A D Sharrocks iD, G Nestal de Moraes iD

The FASEB Journal · 31.10.2026 · 40 (20)

DOI: 10.1096/fj.202600413rrr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 13.10.2026. Verfasst von L T Carneiro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Sinalização e Biologia Tumoral, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Rio de…. Hauptthemen laut MEDLINE: Breast Neoplasms, Proto-Oncogene Proteins c-akt, Forkhead Transcription Factors, Cell Proliferation. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) L'óreal-UNESCO_ABC For women in science Brazil, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), INCT program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FOXK2 is a transcription factor known to mediate drug sensitivity in breast cancer. However, poor prognosis patients and drug‐resistant cells exhibit constitutively elevated levels of FOXK2 protein, which appears functionally inactive. Although emerging evidence suggests that FOXK2 is regulated by post‐translational modifications, the underlying mechanisms in breast cancer remain poorly understood. An in silico analysis identified AKT as a putative regulator of FOXK2, prompting the investigation of AKT‐mediated phosphorylation of FOXK2 in cancer. Our results show that elevated FOXK2 protein levels are associated with increased AKT phosphorylation and doxorubicin resistance. Modulation of AKT levels reduces FOXK2 at protein but not mRNA levels. Consistently, analysis of public breast tumor datasets revealed increased FOXK2 phosphorylation at different sites, including serine 398. Immunoblotting with an antibody against AKT substrates and lambda phosphatase treatment indicates that serine 398 in FOXK2 is an AKT phosphorylation site. Notably, the phosphodeficient FOXK2 mutant (S398A) impaired cell growth, metabolic cell viability, and clonogenic capacity, even in the presence of chemotherapeutic drugs. In summary, AKT regulates FOXK2 in drug‐resistant breast cancer cells, with serine 398 emerging as a novel phosphorylation site. Our findings reveal key insights into FOXK2 regulation and the contribution to understanding breast cancer cell biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProto-Oncogene Proteins c-aktForkhead Transcription FactorsCell ProliferationHumansPhosphorylationFemaleCell SurvivalCell Line, TumorDrug Resistance, NeoplasmSerineDoxorubicin

Stichwörter der Autor:innen

AKT oncogenic kinaseFOXK2 phosphorylationFOXK2 transcription factorbreast cancer cell growthdrug resistance

Substanzen

Proto-Oncogene Proteins c-aktForkhead Transcription FactorsSerineDoxorubicininterleukin binding factor

Autor:innen und Institutionen

  • Laboratório de Sinalização e Biologia Tumoral, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Divisão de Pesquisa Clínica, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
  • Departamento de Biologia Animal-Instituto de Ciências Biológicas e da Saúde (ICBS)-Campus Seropédica, Universidade Federal Rural do Rio de Janeiro (UFRRJ), Rio de Janeiro, RJ, Brazil.
  • Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Hemato-Oncologia Molecular, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
  • Department of Surgery and Cancer, Imperial College London, London, UK.
  • Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.

ORCID-Profile: L T Carneiro, J M R C Nunes, G De Gregoriis, B S Mendonça, W M Araújo, R C Maia, E W F Lam, R S Carvalho, M A Carvalho, A D Sharrocks, G Nestal de Moraes

Förderung

  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) L'óreal-UNESCO_ABC For women in science Brazil
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • INCT program
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Carneiro, L. T., Nunes, J. M. R. C., De Gregoriis, G., Mendonça, B. S., Araújo, W. M., Maia, R. C., Lam, E. W. F., Carvalho, R. S., Carvalho, M. A., Sharrocks, A. D., & Nestal de Moraes, G. (2026). AKT Phosphorylation of FOXK2 at Ser398 Impacts Breast Cancer Cell Growth and Viability. The FASEB Journal, 40(20). https://doi.org/10.1096/fj.202600413rrr

Vancouver

Carneiro LT, Nunes JMRC, De Gregoriis G, Mendonça BS, Araújo WM, Maia RC, et al. AKT Phosphorylation of FOXK2 at Ser398 Impacts Breast Cancer Cell Growth and Viability. The FASEB Journal. 2026;40(20). doi:10.1096/fj.202600413rrr

BibTeX
@article{Carneiro2026,
  author = {Carneiro, L T and Nunes, J M R C and De Gregoriis, G and Mendonça, B S and Araújo, W M and Maia, R C and Lam, E W F and Carvalho, R S and Carvalho, M A and Sharrocks, A D and Nestal de Moraes, G},
  title = {AKT Phosphorylation of FOXK2 at Ser398 Impacts Breast Cancer Cell Growth and Viability},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {20},
  doi = {10.1096/fj.202600413rrr}
}
Kostenlos starten →